{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T08:51:35Z","timestamp":1768035095756,"version":"3.49.0"},"reference-count":28,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2008,6,28]],"date-time":"2008-06-28T00:00:00Z","timestamp":1214611200000},"content-version":"vor","delay-in-days":4654,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[1995,10]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>OBJECTIVE <\/jats:bold> We have reevaluated the prevalence and pathogenetic importance of TSH receptor blocking antibodies (TRBAb) in autoimmune hypothyroidism, and investigated the changes in TRBAb activities during thyroxine and antithyroid drug treatment.<\/jats:p><jats:p><jats:bold>DESIGN <\/jats:bold> Serum TSH binding inhibitor immunoglobulin (TBII) and thyroid stimulation blocking antibody (TSBAb) were measured serially in all patients with non\u2010goitrous autoimmune thyroiditis (AT) and measured monthly during methimazole treatment in 6 patients.<\/jats:p><jats:p><jats:bold>PATIENTS <\/jats:bold> Ninety patients with non\u2010goitrous AT and 95 patients with goitrous AT were entered consecutively into this study. All patients with non\u2010goitrous AT were treated with thyroxine and followed at intervals of 6 months for 2 years initially and then yearly intervals. The duration of follow\u2010up was 1\u20138 years. Six patients from the TRBAb\u2010positive non\u2010goitrous AT group who were treated with thyroxine were randomly selected and given additional treatments with methimazole (40 mg per day) for 6 months.<\/jats:p><jats:p><jats:bold>MEASUREMENTS <\/jats:bold> Serum TBII was <jats:italic>measured<\/jats:italic> by 8 radioreceptor assay, TSBAb by using FRTL\u20105 cells, and antithyroid peroxidase and antithyroglobulin antibodies by radioimmunoassay.<\/jats:p><jats:p><jats:bold>RESULTS <\/jats:bold> The prevalences of TBII and TSBAb in non\u2010goitrous AT were 47\u20138 and 58.9%, respectively, which were significantly higher than those in goitrous AT (6.3% for TBII, 10.5% for TSBAb). All but one patient showed persistent TBII and TSBAb activities during the thyroxine treatment for up to 8 years. A high dose of methimazole (40 mg per day) did not affect the titres of TBII and TSBAb in 5 out of 6 patients with non\u2010goitrous AT tested. However, antithyroid peroxidase and antithyroglobulin antibodies activities were significantly decreased during the methimazole treatment.<\/jats:p><jats:p><jats:bold>CONCLUSION <\/jats:bold> The high prevalence of TSH receptor blocking antibodies (TRBAb) suggests that TRBAb may play a major role in the development of hypothyroidism and thyroid atrophy in the vast majority of patients with non\u2010goitrous autoimmune thyroiditis. Most TRBAb activities are stable for at least 8 years and are not affected by thyroxine and antithyroid drug treatment.<\/jats:p>","DOI":"10.1111\/j.1365-2265.1995.tb02619.x","type":"journal-article","created":{"date-parts":[[2008,3,17]],"date-time":"2008-03-17T10:12:21Z","timestamp":1205748741000},"page":"465-471","source":"Crossref","is-referenced-by-count":24,"title":["High prevalence and little change in TSH receptor blocking antibody titres with thyroxine and antithyroid drug therapy in patients with non\u2010goitrous autoimmune thyroiditis"],"prefix":"10.1111","volume":"43","author":[{"given":"Bo Youn","family":"Cho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won Bae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Hoon","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ka\u2010Hee","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Kee","family":"Shong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong Kyu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang\u2010Soon","family":"Koh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,6,28]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.77.6.3455"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-60-5-953"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1210\/edrv-6-2-183"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-71-1-40"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.77.3.611"},{"key":"e_1_2_1_7_1","first-page":"99","article-title":"Inhibition of thyrotropin\u2010stimulated adenylate cyclase activation and growth of rat thyroid cells, FRTL\u20105, by immunoglobulin G from patients with primary myxedema: comparison with activities of thyrotropin binding inhibitor immunoglobulins","volume":"120","author":"Cho B.Y.","year":"1989","journal-title":"Acia Endocrinologica"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-46-5-734"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1981.tb02968.x"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-57-3-544"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1987.tb01168.x"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198009253031306"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(80)91551-2"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198008073030603"},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.1990.tb05175.x"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-29-2-231"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-58-2-332"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1210\/edrv-9-1-106"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1984.tb00102.x"},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.288.6430.1559"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)92567-2"},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-64-2-239"},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199202203260803"},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-71-5-1382"},{"key":"e_1_2_1_25_1","first-page":"372","article-title":"Expression and function of membrane attack complex inhibitory proteins on thyroid follicular cells","volume":"75","author":"Tandon N.","year":"1992","journal-title":"Immunology"},{"key":"e_1_2_1_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199202203260810"},{"key":"e_1_2_1_27_1","doi-asserted-by":"publisher","DOI":"10.1677\/joe.0.1270357"},{"key":"e_1_2_1_28_1","first-page":"788","article-title":"Autoimmune thyroid disease: Further developments in our understanding","volume":"15","author":"Weetman A.P.","year":"1994","journal-title":"Endocrine Reviews"},{"key":"e_1_2_1_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.287.6394.720"}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2265.1995.tb02619.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2265.1995.tb02619.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T13:21:06Z","timestamp":1695907266000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2265.1995.tb02619.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,10]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1995,10]]}},"alternative-id":["10.1111\/j.1365-2265.1995.tb02619.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2265.1995.tb02619.x","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,10]]}}}